Loading clinical trials...
Loading clinical trials...
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Conditions
Interventions
Blinatumomab
Cyclophosphamide
+7 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
February 8, 2018
Primary Completion Date
February 28, 2027
Completion Date
February 28, 2027
Last Updated
February 17, 2026
NCT06735690
NCT06074666
NCT04972942
NCT07295951
NCT07523555
NCT06395103
Lead Sponsor
M.D. Anderson Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions